Relationship between exhaled nitric oxide and the frequency of severe acute exacerbation of COPD: 3-year follow-up.

作者: Balázs Antus , I. Barta

DOI: 10.1556/APHYSIOL.100.2013.016

关键词:

摘要: In a recent trial we have assessed fractional exhaled nitric oxide (FENO) in cohort of patients with an acute exacerbation chronic obstructive pulmonary disease (COPD). the current study retrospectively investigated frequency severe hospitalization-associated exacerbations same over 3 years after initial FENO measurement. A total 58 COPD were enrolled and allocated either into low (< 27 ppb) or high (≥ group depending on their level at exacerbation. Beside annual rate exacerbations, sputum culture results antibiotic treatments also analyzed during follow-up. Both number per patient-year hospitalization days due to significantly increased from compared those group. Sputum samples derived more frequently indicative bacterial infection obtained other subgroup. Also, was subjects Results this pilot suggest that diverse risks for future levels

参考文章(25)
Alvar Agusti, Patricia Sobradillo, Bartolomé Celli, Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. American Journal of Respiratory and Critical Care Medicine. ,vol. 183, pp. 1129- 1137 ,(2011) , 10.1164/RCCM.201009-1414PP
Ken M. Kunisaki, Kathryn L. Rice, Edward N. Janoff, Thomas S. Rector, Dennis E. Niewoehner, Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: A prospective study Therapeutic Advances in Respiratory Disease. ,vol. 2, pp. 55- 64 ,(2008) , 10.1177/1753465808088902
John R. Hurst, Jørgen Vestbo, Antonio Anzueto, Nicholas Locantore, Hana Müllerova, Ruth Tal-Singer, Bruce Miller, David A. Lomas, Alvar Agusti, William MacNee, Peter Calverley, Stephen Rennard, Emiel F.M. Wouters, Jadwiga A. Wedzicha, Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease The New England Journal of Medicine. ,vol. 363, pp. 1128- 1138 ,(2010) , 10.1056/NEJMOA0909883
N. R. ANTHONISEN, Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease Annals of Internal Medicine. ,vol. 106, pp. 196- 204 ,(1987) , 10.7326/0003-4819-106-2-196
P. G. Woodruff, Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proceedings of the American Thoracic Society. ,vol. 8, pp. 350- 355 ,(2011) , 10.1513/PATS.201101-015RM
E. K. Silverman, Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proceedings of the American Thoracic Society. ,vol. 4, pp. 586- 590 ,(2007) , 10.1513/PATS.200706-068TH
Chris Miller, Minna Miller, Bevin McMullin, Gilly Regev, Lena Serghides, Kevin Kain, Jeremy Road, Yossef Av-Gay, A phase I clinical study of inhaled nitric oxide in healthy adults Journal of Cystic Fibrosis. ,vol. 11, pp. 324- 331 ,(2012) , 10.1016/J.JCF.2012.01.003
Keisaku Fujimoto, Keishi Kubo, Hiroshi Yamamoto, Shinji Yamaguchi, Yukinori Matsuzawa, Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest. ,vol. 115, pp. 697- 702 ,(1999) , 10.1378/CHEST.115.3.697
EMILIO PIZZICHINI, MARCIA M. M. PIZZICHINI, PETER GIBSON, K. PARAMESWARAN, GERALD J. GLEICH, LES BERMAN, JERRY DOLOVICH, FREDERICK E. HARGREAVE, Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis American Journal of Respiratory and Critical Care Medicine. ,vol. 158, pp. 1511- 1517 ,(1998) , 10.1164/AJRCCM.158.5.9804028